Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

peglispro

- PMLiVE

Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

- PMLiVE

Novo Nordisk awakens its ‘Sleeping Beauty’

Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott

- PMLiVE

New drugs drive Novo Nordisk despite insulin price pressures

Sales growth of new products up in Q4 but trouble forecasted this year

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

Novo Nordisk gets MACE prevention claim for Ozempic in US

Key product for the future growth of Novo's diabetes franchise

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

Novo bolstered by new diabetes, obesity products

Danish drug-maker has now raised its full-year sales forecast

- PMLiVE

Novo Nordisk taps Noom for digital help with its push into obesity

Could help to strengthen Saxenda franchise in treatment of obesity

- PMLiVE

Novo Nordisk gets FDA okay for new diabetes hope

Potential to combat increasing competition and pricing pressures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links